A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

Status:
Completed

Trial end date:
2004-03-15

Target enrollment:

Participant gender:

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

Phase 3

Merck Sharp & Dohme Corp.

Alendronate